Multiple Manufacturers



Multiple Manufacturers

Renflexis HCPCS:


HCPCS Code Descriptor:

Injection, infliximab-abda, biosimilar, (renflexis), 10 mg


Q Code

Renflexis NDCs:

00006-4305-02, 78206-0162-01

Primary Type:

Immunology Anti-TNF Biosimilar

Generic/Specialty Status:


Package Type:


Route of Administration:


Renflexis CPT Codes:

Potential CPT administration codes for Renflexis can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Renflexis:

RENFLEXIS is a medication manufactured by multiple manufacturers and aligned to the Q Code: Q5104. RENFLEXIS is administered via the intravenous route of administration.

Renflexis (infliximab) is a monoclonal antibody that is used to treat a range of inflammatory autoimmune disorders. Renflexis binds to tumor necrosis factor-alpha and hinders it from activating certain processes. This medication is administered via intravenous infusion over the course of multiple weeks. Renflexis is manufactured by Merck Sharp & Dohme and Organon and is biosimilar to Remicade (J1745). The Q Code that was assigned to this medication (Q5104) has been effective since April 2018. Patient assistance programs for this medication can be found through the Organon access program.


Q5104 Added Date:

April 1, 2018

Q5104 Effective Date:

April 1, 2018

Q5104 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Renflexis billing and coding information.
Renflexis patient assistance information can be found through The Organon Access Program at the URL:
RENFLEXIS prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date.
Our team has not yet identified a source of side effects information for RENFLEXIS. Please check back in a few weeks.